Search results
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 21 hours agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 7 days agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 4 days ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Merck KGaA taps AI-focused biotech for new ADC pact worth $376M
FierceBiotech· 2 days agoMerck KGaA is hoping to sprout some new oncology and immunology therapeutics with Biolojic Design’s AI-driven drug discovery engine. Merck has signed the ...
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Morningstar· 3 days agoModerna and Merck said they saw positive results from a Phase 2b study evaluating mRNA-4157 in combination with Keytruda in patients with high-risk skin cancer that was surgically ...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 3 days agoInsights from TIME, The Washington Post, MIT Technology Review The News Pharmaceutical giants...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 10 hours agoRevenues from the transfer of intellectual property and others totaled $8.7 million, down from $64.8...
MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
BioresearchOnline· 3 days agoMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany,...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 4 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...